Under an important initiative aimed at transforming healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a letter of intent to collaborate on the localisation of cell and gene therapies.

The signing ceremony was attended by Abdulaziz Al-Ramaih, Deputy Minister of Health for Planning and Development, Saudi Arabia, which represents an important step forward in Saudi Arabia's efforts to improve healthcare capacity and achieve the ambitious goals set out in Vision 2030.

Dr Fahad Al-Ghofaili, Chief Executive Officer of KFMC, said, "KFMC's localised cell and gene therapies are an important step in enhancing the region's advanced therapeutics and medical technology capabilities to achieve the goals of healthcare transformation projects."

Known for its customer-first approach, Boston Oncology has extensive expertise in technology localisation. With the real needs of patients and hospitals at the center, Boston Oncology provides cutting-edge technology and cell and gene therapies through this collaboration. The collaboration will establish local treatment options, alleviate bottlenecks in treatment supply, and improve patient outcomes. The resulting R&D and clinical trials will significantly contribute to the advancement of innovation in healthcare in Saudi Arabia.